Alkermes (ALKS) PT Cut to $58 at Leerink Partners; Maintains 'Outperform'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
UBS Remains Sidelined on Alkermes plc (ALKS) Following Failed ALKS 5461 Studies
January 22, 2016 9:40 AM ESTUBS maintained a Neutral rating on Alkermes (NASDAQ: ALKS), and cut the price target to $36.00 (from $65.00). With the failure of FORWARD-3 and FORWARD-4 studies for ALKS 5461 in MDD, UBS believes that there is a very low possibility of getting this product approved even... More
Morgan Stanley Downgrades Alkermes (ALKS) to Underweight
January 21, 2016 12:52 PM ESTMorgan Stanley downgraded Alkermes (NASDAQ: ALKS) from Overweight to Underweight with a price target of $35.00.
For an analyst ratings summary and ratings history on Alkermes click here. For more ratings news on Alkermes click here.
Shares of Alkermes closed at $60.42 yesterday.
... MoreCowen Downgrades Alkermes (ALKS) to Market Perform
January 21, 2016 9:51 AM ESTCowen downgraded Alkermes (NASDAQ: ALKS) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Alkermes click here. For more ratings news on Alkermes click here.
Shares of Alkermes closed at $60.42 yesterday.
... MoreAlkermes' (ALKS) Two Phase 3 Studies of ALKS 5461 in MDD Failed to Meet Primary Efficacy Endpoint
January 21, 2016 7:03 AM ESTAlkermes plc (Nasdaq: ALKS) announced preliminary topline results from FORWARD-3 and FORWARD-4, the first two of three phase 3 efficacy studies to read out from the comprehensive FORWARD pivotal program for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD) in patients who have an... More
